Showing 631-640 of 974 results for "".
- Study Compares the Accuracy of Subjective Refraction Using a Vmax Vision’s VASR vs. Traditional Refractionhttps://modernod.com/news/study-compares-the-accuracy-of-subjective-refraction-using-a-vmax-visions-vasr-vs-traditional-refraction/2480157/A comparison study reported at ARVO 2018, conducted by Drs. Christopher Lievens, Christina Newman, Alan Kabat, and optometry student Jacob Weber at the Southern College of Optometry (SCO), included 50 healthy subjects
- Nordic Group Appoints Eric Donnenfeld, MD, as Medical Advisory Board Chairhttps://modernod.com/news/nordic-group-appoints-eric-donnenfeld-md-as-medical-advisory-board-chair/2482132/Amring Pharmaceuticals, a subsidiary of Nordic Group, announced that ophthalmologist Eric D. Donnenfeld, MD, will chair its US Medical Advisory Board, which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, O
- Aviceda Therapeutics Appoints Biopharma and Business Veterans to its Board of Directorshttps://modernod.com/news/aviceda-therapeutics-appoints-biopharma-and-business-veterans-to-its-board-of-directors/2478284/Aviceda Therapeutics has announce the appointment of Chris Adams, PhD, MBA, and Nancy K. Thomason, MBA, to their board of directors, effective immediately. Aviceda is a preclinical stage biotech company focused on the next generation of glyco-immune therapeutics utilizing the Glyco-Code technolog
- Oyster Point Pharma Expands Executive Leadership Teamhttps://modernod.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset mana
- Nacuity Pharmaceuticals Strengthens Scientific Advisory Board with Appointment of Nancy Holekamp, MD, and Richard L. Lindstrom, MDhttps://modernod.com/news/nacuity-pharmaceuticals-strengthens-scientific-advisory-board-with-appointment-of-nancy-holekamp-md-and-richard-l-lindstrom-md/2480903/Nacuity Pharmaceuticals announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Nancy Holekamp, MD, and Richard L. Lindstrom, MD. “We are thrilled and grateful to welcome two world-renowned ophthalmologists who bring to our SAB significant and essent
- Nicox Appoints Robert N. Weinreb, MD, and Sanjay G. Asrani, MD, to its Glaucoma Clinical Advisory Boardhttps://modernod.com/news/nicox-appoints-robert-n-weinreb-md-and-sanjay-g-asrani-md-to-its-glaucoma-clinical-advisory-board/2479362/Nicox SA announced that two internationally recognized experts in glaucoma, Robert N. Weinreb, MD, Distinguished Professor and Chair, Ophthalmology and Director, Shiley Eye Institute, University of California San Diego; and Sanjay G. Asrani, MD, Professor of Ophthalmology, Duke University, will b
- Elizabeth Yeu, MD, and K. Peony Yu, MD, Appointed to Staar Surgical Board of Directorshttps://modernod.com/news/elizabeth-yeu-md-and-k-peony-yu-md-appointed-to-staar-surgical-board-of-directors/2478798/Staar Surgical announced the appointments of Elizabeth Yeu, MD, Partner, Virginia Eye Consultants, and K. Peony Yu, MD, retired Chief Medical Officer, FibroGen, to its Board of Directors, effective January 21, 2021. “The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our Board of Dir
- Tangible Science Announces CEO Transitionhttps://modernod.com/news/tangible-science-announces-ceo-transition/2482613/Tangible Science, a provider of specialty contact lens technology, announced that Karen Havenstrite, PhD, MBA, co-founder and former Chief Technology Officer, has been appointed Chief Executive Officer. Dr. Havenstrite suceeds Victor McCray, MD, who will transition to the
- EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeuticshttps://modernod.com/news/eyegate-pharmaceuticals-closes-acquisition-of-bayon-therapeutics/2480376/EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’
- Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairshttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-michelle-senchyna-phd-as-vice-president-clinical-development-and-medical-affairs/2477271/Aerie Pharmaceuticals announced the appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, MD, MBA, Aerie’s Chief Research & Development Officer. Dr. Senchyna will lead and direct the clinical development and